A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07668388
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT07668388
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Germany, Hungary, Poland, Romania, Slovakia, South Korea, Spain
- Registry status
- Recruiting
Technical summary
Registry record NCT07668388. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-22 (actual); primary completion 2027-10-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- UBT251
- Intervention (Drug)
- UBT251 Placebo
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Semaglutide Placebo
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct07668388- Content hash
1641e104f412232ee3e855417de4923efe95ededac775d3776c20f646e910009